C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of$ 0.37. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.73%. A quarter ago, it was expected that this company would post a loss of$ 0.41 per share when it actually produced a loss of $0.41, delivering no surprise. Over the last four quarters, the company has surpassed ...